Clinical Analysis Of Troxerutin And Cerebroprotein Injection In The Treatment Of Acute Cerebral Infarction

Objective: To observe the efficacy of compound Troxerutin and Cerebroprotein Injection in the treatment of acute cerebral infarction and evaluate its safety.Method: Collected in December 2015 to December 2016 admitted to the Second Hospital of Jilin University Department of Neurology,through the head CT or magnetic resonance imaging(MRI)showed new lesions in patients with cerebral infarction,a total of 100 cases,according to age,sex,onset time,Risk factors for cerebrovascular disease were divided into two groups,each group were 50 cases.According to the 2014 "Guidelines for the Prevention and Treatment of Ischemic Stroke in China",the basic treatment is given,if necessary,combined with individualized treatment,including anti-platelet aggregation,improve circulation,regulate blood lipids,regulate blood pressure,control blood sugar,reduce brain edema and other treatment.In the experimental group,10 ml Troxerutin and o Injection + 250 ml 0.9% Physiological saline was given once daily intravenous infusion;the control group was given 1.2g calf serum to protein hydrolyzate injection + 250 ml 0.9% 250 ml 0.9% Physiological saline,each Day intravenous infusion,the two groups of patients were treated for 14 days,were admitted to the hospital before treatment and 14 days after treatment NIHSS score.All the data were analyzed by SPSS21.0 statistical software package.The data of the normal distribution were expressed by mean ± standard deviation(x ±s).Before and after treatment,the paired t test was used in the experimental group.And the control group between the use of independent t test,count data using ?2 test,were P <0.05 for the difference was statistically significant.The therapeutic effect and safety were evaluated by observing the degree of recovery of neurological deficits before and after treatment.Result:(1)All the statistical data of the patients in the experimental group and the control group were analyzed.Two groups of patients were divided into two groups: age,sex,risk factors of cerebrovascular disease(such as hypertension,diabetes,smoking,drinking,etc.)Of the NIHSS score and other measurement data for ?2 test,p values were greater than 0.05,no significant difference.The NIHSS score was further scored after 14 days of treatment.The results showed that the scores of the two groups were reduced,and the mean value of NIHSS score in the experimental group was higher than that in the control group.T test method,P value <0.01,statistically significant.The results showed that Troxerutin and Cerebroprotein Injection was more effective in the treatment of neurological deficits during the treatment of acute cerebral infarction,which was superior to the control group.(2)Safety evaluation: 50 patients in this experimental group selected,in the course of treatment,there is no serious liver and kidney dysfunction,gastrointestinal bleeding,blood and coagulation routine abnormalities,allergies,etc.,no obvious side effects and Adverse reactions.Conclusion:(1)Compared with the pure neuroprotective effect of calf serum to protein hydrolyzate injection,Troxerutin and Cerebroprotein Injection in the acute phase of cerebral infarction during the treatment of neurological defects to restore functional recovery has a more significant clinical efficacy.(2)Troxerutin and Cerebroprotein Injection in the course of treatment without significant adverse reactions and side effects,the clinical application of safe and reliable.